N4-(5-bromo-2-methoxyphenyl)-5-chloro-N2-(3-vinylphenyl)pyrimidine-2,4-diamine | 1192322-90-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: N4-(5-bromo-2-methoxyphenyl)-5-chloro-N2-(3-vinylphenyl)pyrimidine-2,4-diamine
• 英文别名: (14Z)-6-Chloro-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,14,16,18-decaene；(14Z)-6-chloro-2,4,8,22-tetrazatetracyclo[14.3.1.13,7.19,13]docosa-1(19),3,5,7(22),9,11,13(21),14,16(20),17-decaene
• CAS: 1192322-90-9
• 化学式: C₁₈H₁₃ClN₄
• 分子量: 320.781
• InChiKey: UXTUSZRFHSSTCU-FPLPWBNLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  23.0
• 可旋转键数：
  0.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.84
• 氢给体数：
  2.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  N4-(5-bromo-2-methoxyphenyl)-5-chloro-N2-(3-vinylphenyl)pyrimidine-2,4-diamine 在 potassium osmate(VI) dihydrate N-甲基吗啉氧化物 作用下， 以 四氢呋喃 、 水 、 丙酮 为溶剂， 反应 3.5h， 以5%的产率得到(14R,15S)-6-chloro-2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene-14,15-diol
  参考文献：
  名称：

  [EN] MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS
  [FR] COMPOSÉS MACROCYLCIQUES COMME INHIBITEURS D'ALK, DE FAK ET DE JAK2

  摘要：

  本发明提供了式I的化合物或其药用可接受的盐形式，其中R1、R2、R3、R4、R5、A和X如本文所定义，以及其治疗方法和用途。

  公开号：

  WO2012125603A1
• 作为产物：
  描述：

  N-(3-bromophenyl)-2,5-dichloropyrimidin-4-amine 在 盐酸 、 palladium diacetate 、 三乙胺 、 三(邻甲基苯基)磷 作用下， 以 1,4-二氧六环 、 甲乙醚 、 乙腈 为溶剂， 反应 16.5h， 生成 N4-(5-bromo-2-methoxyphenyl)-5-chloro-N2-(3-vinylphenyl)pyrimidine-2,4-diamine
  参考文献：
  名称：

  Design, Synthesis, and Anaplastic Lymphoma Kinase (ALK) Inhibitory Activity for a Novel Series of 2,4,8,22-Tetraazatetracyclo[14.3.1.1^3,7.1^9,13]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene Macrocycles

  摘要：

  A novel set of 2,4,8,22-tetraazatetracyclo[14.3.1.1(3,7).1(9,13)]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles were prepared as potential anaplastic lymphoma kinase (ALK) inhibitors, designed to rigidly lock an energy-minimized bioactive conformation of the diaminopyrimidine (DAP) scaffold, a well-documented kinase platform. From 13 analogues prepared, macrocycle 2m showed the most promising in vitro ALK enzymatic (IC50 = 0.5 nM) and cellular (IC50 = 10 nM) activities. In addition, macrocycle 2m exhibited a favorable kinase selectivity preference for inhibition of ALK relative to the highly homologous insulin receptor (IR) kinase (IR/ALK ratio of 173). The inclusive in vitro biological results for this set of macrocycles validate this scaffold as a viable kinase template and further corroborate recent DAP/ALK solid state studies indicating that the inverted "U" shaped conformation of the acyclic DAPs is a preferred bioactive conformation.

  DOI：

  10.1021/jm201333e

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• Macrocyclic Compounds as ALK, FAK and JAK2 Inhibitors
  申请人：Cephalon, Inc.

  公开号：US20140031351A1

  公开（公告）日：2014-01-30

  The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.

  本发明提供了I式化合物或其药学上可接受的盐形式，其中R1、R2、R3、R4、R5、A和X的定义如本文所述，以及其治疗方法和用途。
• MACROCYCLIC COMPOUNDS AS ALK, FAK AND JAK2 INHIBITORS
  申请人：Cephalon, Inc.

  公开号：US20170027948A1

  公开（公告）日：2017-02-02

  The present invention provides compounds of Formula I or a pharmaceutically acceptable salt forms thereof, wherein R1, R2, R3, R4, R5, A and X are as defined herein, methods of treatment and uses thereof.
• US8871753B2
  申请人：——

  公开号：US8871753B2

  公开（公告）日：2014-10-28
• US9487529B2
  申请人：——

  公开号：US9487529B2

  公开（公告）日：2016-11-08